...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Wikipedia on Investor Relations: Goal is Fair Valuation

narmac...you commented ",I do hold onto the idea that ZEL will be in some sort of discovery mode well prior to BoM results,".

I do tend to agree with you. Don did say that cancer trials move much faster than cardiovascular trials.

So what I am thinking is that Don said in his last update the there will be a Zenith IPO in 2016. For him to say that he must think that the castration resistant metatstatic prostate cancer trial will show positive results fairly quickly. We are now 2/3rds through Q2 but have not had an update. This of course is frustrating.

I sure hope we get some good early signs on this trial. It will have a positive effect all the way round.

GLTA

Toinv

Share
New Message
Please login to post a reply